Company Analysis
Sign in

Viking Therapeutics, Inc. (VKTX)

Nasdaq: VKTX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2014
Full chart Alerts Compare
Grade6.3
◀ Past 5.8● Present 7.0▶ Future 6.0
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

11 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Viking Therapeutics, Inc.’s names, not what it holds today.

Patents granted
11
11 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 2 in 2024 and 3 in 2023
Applications published
22
4 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals9
Organic fine chemistry2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Viking Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
21 published
Viking Therapeutics, Inc. its own name
US, as the owner printed on each patent
11 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 14, 202512,440,502Use of thyroid beta-agonistsPharmaceuticalsViking Therapeutics, Inc.
Sep 23, 202512,421,282Compositions and methods for the treatment of metabolic and liver disordersPharmaceuticalsViking Therapeutics, Inc.
Jun 3, 202512,318,426Compositions and methods for the treatment of metabolic and liver disordersPharmaceuticalsViking Therapeutics, Inc.
Feb 18, 202512,227,533Crystalline forms and methods of producing crystalline forms of a compoundOrganic fine chemistryViking Therapeutics, Inc.
Oct 1, 202412,102,646Compositions for the treatment of fibrosis and inflammationPharmaceuticalsViking Therapeutics, Inc.
Apr 9, 202411,951,114Use of thyroid beta-agonistsPharmaceuticalsViking Therapeutics, Inc.
Oct 17, 202311,787,828Crystalline forms and methods of producing crystalline forms of a compoundOrganic fine chemistryViking Therapeutics, Inc.
Sep 5, 202311,744,873Compositions and methods for the treatment of metabolic and liver disordersPharmaceuticalsViking Therapeutics, Inc.
Jul 25, 202311,707,472Compositions for the treatment of fibrosisPharmaceuticalsViking Therapeutics, Inc.
Jun 7, 202211,351,183Use of thyroid beta-agonistsPharmaceuticalsViking Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
May 29, 20252025/0171499PHARMACEUTICAL FORMULATIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERSPharmaceuticalsViking Therapeutics, Inc.
May 1, 20252025/0134913ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAMEPharmaceuticalsViking Therapeutics, Inc.
Jan 30, 20252025/0034183POLYMORPHIC FORMS AND METHODS OF PRODUCING POLYMORPHIC FORMS OF A COMPOUNDOrganic fine chemistryViking Therapeutics, Inc.
Jan 2, 20252025/0000880USE OF THYROID BETA-AGONISTSPharmaceuticalsViking Therapeutics, Inc. · patent 12,440,502 granted from it
Nov 7, 20242024/0366714COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERSPharmaceuticalsViking Therapeutics, Inc. · patent 12,318,426 granted from it
Jul 18, 20242024/0239843COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERSPharmaceuticalsViking Therapeutics, Inc. · patent 12,421,282 granted from it
Jun 13, 20242024/0189332COMPOSITIONS FOR THE TREATMENT OF FIBROSISPharmaceuticalsViking Therapeutics, Inc.
Feb 22, 20242024/0058415COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERSPharmaceuticalsViking Therapeutics, Inc.
Feb 8, 20242024/0043459CRYSTALLINE FORMS AND METHODS OF PRODUCING CRYSTALLINE FORMS OF A COMPOUNDOrganic fine chemistryViking Therapeutics, Inc. · patent 12,227,533 granted from it
Jul 20, 20232023/0226038COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERSPharmaceuticalsViking Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Organic fine chemistry 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton VKTX · research, not advice